PF-562271 HCl: ATP-Competitive FAK/Pyk2 Inhibitor for Cancer Research

Understanding PF-562271 HCl: Principle and Experimental Rationale

PF-562271 HCl, available from APExBIO, is a nanomolar-potent, ATP-competitive, and reversible inhibitor targeting focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2). FAK and Pyk2 play pivotal roles in cell adhesion, migration, survival, and tumor progression, making them critical nodes in the focal adhesion kinase signaling pathway. PF-562271 HCl exhibits an impressive IC₅₀ of 1.5 nM for FAK and 14 nM for Pyk2, providing approximately 10-fold selectivity for FAK and over 100-fold selectivity against most other kinases, except some cyclin-dependent kinases (CDKs).

This high specificity enables researchers to interrogate the mechanistic underpinnings of FAK/Pyk2 signaling in cancer biology, metastasis, and the tumor microenvironment, while minimizing off-target effects. Notably, PF-562271 HCl has demonstrated robust FAK phosphorylation inhibition in vivo, with an EC₅₀ of 93 ng/mL in tumor-bearing mouse models, resulting in marked tumor growth inhibition and reduced metastatic potential. Such attributes position this compound as an essential tool for both foundational and translational cancer research.

Optimized Workflow: Step-by-Step Protocol Enhancements

1. Compound Preparation

• Solubility: PF-562271 HCl is supplied as a solid and is highly soluble in DMSO (≥26.35 mg/mL with gentle warming); it is insoluble in water and ethanol.
• Storage: Store the solid at -20°C; avoid long-term storage of solutions to maintain compound integrity.
• Working Solution: Prepare stock solutions in DMSO just prior to use. For cell-based assays, dilute stocks into culture medium to achieve desired final concentrations, ensuring DMSO content remains ≤0.1% to avoid cytotoxicity.

2. Cell-Based FAK/Pyk2 Inhibition Assay

1. Select Cell Model: Choose cancer cell lines known for FAK/Pyk2 dependence (e.g., melanoma, breast, or prostate cancer lines).
2. Treatment: Treat cells with a range of PF-562271 HCl concentrations (typically 0.1 nM to 10 μM) for 1–24 hours, depending on assay endpoint.
3. Readout: Assess FAK phosphorylation status using Western blot or ELISA. Quantify downstream effects such as cell migration (wound healing assay), invasion (transwell assay), or viability (MTT/XTT).
4. Controls: Include vehicle (DMSO) and positive/negative controls to validate specificity.

3. In Vivo Tumor Growth Inhibition

• Dosing: Administer PF-562271 HCl via intraperitoneal or oral routes in tumor-bearing mice. Typical dosing regimens range from 10–50 mg/kg daily, as supported by published efficacy data (EC₅₀ = 93 ng/mL for FAK phosphorylation inhibition in vivo).
• Endpoints: Monitor tumor volume, metastasis, and FAK pathway activity (immunohistochemistry or phospho-FAK staining).

For a deeper dive into protocol enhancements and translational strategies, see "From Mechanism to Medicine: Harnessing PF-562271 HCl for Oncology", which provides comprehensive experimental best practices and strategic advantages of this ATP-competitive FAK inhibitor.

Advanced Applications and Comparative Advantages

PF-562271 HCl’s high selectivity and reversibility make it a preferred tool for dissecting the focal adhesion kinase signaling pathway in diverse cancer research applications. Its ability to precisely inhibit both FAK and Pyk2 enables:

• Tumor Microenvironment Modulation: By targeting FAK/Pyk2, PF-562271 HCl disrupts tumor-stroma interactions, modulates immune cell infiltration, and sensitizes tumors to immunotherapies—key insights supported by studies such as the Anichini et al. (2022) melanoma immunotherapy analysis. While this study focused on epigenetic regulators, it highlights the importance of kinases like FAK in shaping immune signatures and therapeutic responsiveness.
• Synergy with Immunomodulatory Agents: The compound’s role in FAK phosphorylation inhibition complements epigenetic and checkpoint blockade therapies, offering combinatorial potential for overcoming resistance in solid tumors.
• Modeling Metastasis and Therapy Resistance: Its use in in vivo metastasis models and drug-resistant cancer cell lines supports functional dissection of cell migration, invasion, and survival mechanisms.

These advantages are further illustrated in "PF-562271 HCl: ATP-Competitive FAK/Pyk2 Inhibitor for Cancer Research". This resource details how PF-562271 HCl enables precise modulation of FAK/Pyk2 signaling, validated in tumor growth inhibition and microenvironment modulation studies, solidifying its role in translational oncology.

Comparative Insights with Other Tools

Compared to less selective kinase inhibitors, PF-562271 HCl’s 10-fold selectivity for FAK over Pyk2 and over 100-fold selectivity against other kinases reduces off-target effects and experimental confounders. As discussed in "PF-562271 HCl: Decoding FAK/Pyk2 Inhibition in Immunomodulation", this specificity is critical for studies dissecting tumor-immune interactions and ERK-mediated cell death, offering clearer mechanistic insights.

Troubleshooting and Optimization Tips

• Compound Solubility: If precipitation occurs, gently warm the DMSO stock and vortex. Avoid water or ethanol as solvents, as PF-562271 HCl is insoluble in these.
• Solution Stability: Prepare working solutions fresh before use. Prolonged storage, even at -20°C, can result in reduced efficacy due to hydrolysis or oxidation.
• Cell Line Sensitivity: FAK/Pyk2 dependence varies across cancer types. Validate inhibition by monitoring phospho-FAK and downstream effectors (e.g., paxillin, ERK) to ensure pathway targeting.
• DMSO Controls: Always include matched DMSO vehicle controls to account for solvent effects, especially in cell viability or migration assays.
• Assay Timing: For acute signaling studies, shorter treatments (1–6 hours) may suffice, while chronic exposure (24–72 hours) is suitable for migration, invasion, or proliferation endpoints.
• In Vivo Considerations: Monitor for potential off-target effects on CDKs at higher doses. Use pharmacokinetic data to optimize dosing intervals and minimize toxicity.

For additional troubleshooting, the article "PF-562271 HCl: Unraveling FAK/Pyk2 Inhibition in Cancer Immunotherapy" provides guidance on integrating PF-562271 HCl into complex immune-oncology workflows, emphasizing strategies to overcome experimental roadblocks.

Future Outlook: Expanding the Impact of FAK/Pyk2 Inhibition

With the growing need for precision oncology tools, PF-562271 HCl is poised for expanded roles in both bench and translational research. Key directions include:

• Combinatorial Therapies: Integration with immune checkpoint inhibitors, epigenetic modulators, and targeted agents to potentiate anti-tumor immunity—echoing the approach highlighted by Anichini et al. (2022) in their landscape analysis of immunomodulatory drugs in melanoma.
• Biomarker-Guided Research: Leveraging phospho-FAK and FAK/Pyk2 pathway signatures as predictive biomarkers for therapy response and resistance mechanisms.
• Tumor Microenvironment Engineering: Dissecting the cross-talk between cancer cells, stroma, and immune infiltrates to design next-generation therapeutics.
• Emerging Disease Models: Application in patient-derived xenografts, organoids, and immunocompetent models to bridge preclinical findings with clinical translation.

For researchers seeking to drive innovation in cancer biology and therapy, PF-562271 HCl from APExBIO offers validated performance, robust selectivity, and a foundation for breakthrough discoveries.

Conclusion

PF-562271 HCl is an indispensable FAK/Pyk2 inhibitor that delivers precise, ATP-competitive inhibition of focal adhesion kinase signaling, facilitating advanced cancer research and translational innovation. Its nanomolar potency, selectivity, and proven efficacy in tumor growth and microenvironment modulation empower researchers to dissect complex oncogenic pathways and design next-generation combinatorial therapies. By integrating PF-562271 HCl into experimental workflows—and leveraging published resources for optimization and troubleshooting—labs can accelerate progress in understanding and targeting the tumor microenvironment, overcoming therapeutic resistance, and engineering durable anti-cancer responses.